Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A β2-agonist as a CFTR activator in cystic fibrosis
2014-000057-37Phase 2Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of salbutamol in cystic fibrosis (CF) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Change in nasal potential difference and Change in sweat chloride concentration. Started Feb 2014; status: completed.
02
Drugs
salbutamol
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2014-000057-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000057-37.